Open AccessEffect of a New Psychoactive Compound, MCI-225, on Brain Monoamine Metabolism in Rats
Author(s) -
Ryozo Oishi,
Yoshinori Itoh,
Naoto Adachi,
Kiyomi Saeki
Publication year - 1993
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.63.261
Subject(s) - monoamine neurotransmitter , serotonergic , hypothalamus , medicine , endocrinology , chemistry , probenecid , striatum , microdialysis , hippocampus , metabolism , cerebral cortex , serotonin , 5 hydroxyindoleacetic acid , norepinephrine , central nervous system , dopamine , biology , receptor
Effect of MCI-225 on brain monoamine metabolism was examined in rats. MCI-225 (30 mg/kg, p.o.) had no influence on noradrenaline (NA) levels, but significantly inhibited the NA turnover in the hippocampus and hypothalamus. This compound also significantly increased the 5-hydroxyindoleacetic acid (5-HIAA)/5-hydroxytryptamine ratio in the cerebral cortex, hippocampus and striatum; and it enhanced the probenecid-induced 5-HIAA accumulation in the striatum. In the microdialysis study, MCI-225 markedly increased the NA output, but decreased the 3,4-dihydroxyphenylethyleneglycol output from the hypothalamus of urethane-anesthetized rats. These results suggest that MCI-225 enhances both noradrenergic and serotonergic function by inhibiting NA uptake and accelerating 5-HT turnover, respectively.